By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen has increased the offering price for its proposed acquisition of Australian biotech firm Cellestis.

The offering price has been increased from A$3.55 (US$3.79) per share to A$3.80 per share, under the terms of an amended proposal. The transaction value for the deal has increased to US$374 million from US$355 million, Qiagen said Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.